China Drugmakers’ 2026 Overseas Licensing Deals Reach $139 Billion
Chinese drugmakers’ overseas licensing deals in 2026 have reached $139 billion, surpassing last year’s record. Hengrui Pharma is cited at $44 billion.
Chinese drugmakers’ overseas licensing deals reached $139 bln in 2026, surpassing the record set last year. As major pharmaceutical companies look to China’s labs for advances in areas including cancer and obesity, companies such as Hengrui Pharma, valued at $44 bln, are securing more of the returns from their discoveries.